Xcout Intel
Amalgent Therapeutics, LLC competitors & alternatives
The 12 closest competitors and alternatives to Amalgent Therapeutics, LLC among biotechnology companies — ranked by similarity to what Amalgent Therapeutics, LLC actually does, not by market-cap band.
Subscribe to see Amalgent Therapeutics, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Amalgent Therapeutics, LLC
Amalgent Therapeutics develops fixed-dose combination therapies that pair opioids with dopamine-modulating adjuvants to provide safe pain management. The company's lead program, AMGT-0220, is designed to reduce required opioid doses, mitigate tolerance development, and lower reward signaling to help patients recover without the risks of conventional opioid treatments.
Amalgent Therapeutics, LLC at a glance
Amalgent Therapeutics, LLC is a biotechnology company headquartered in United States. Its most recent funding round raised $200,000 in April 2022. Xcout tracks 4 named people at Amalgent Therapeutics, LLC, including Andrew Graham (Chief Finance Officer).
Amalgent Therapeutics, LLC leadership
- Andrew GrahamChief Finance Officer
- Gerald KleinChief Medical Officer
- Sam TetlowCo-founder President, Executive Chair
- Malcolm MeynCo-founder and Chief Scientific Officer
Amalgent Therapeutics, LLC funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $200,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Amalgent Therapeutics, LLC competitors
Ranked by semantic similarity — how close each company is to Amalgent Therapeutics, LLC by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Daya CNS, LLC is a preclinical biopharmaceutical company that develops a proprietary non-opioid pyridoindole platform for the treatment of chronic pain, substance abuse disorders, and neuropsychiatric conditions. Its product pipeline includes small molecule medications such as DDD-028 for neuropathic and inflammatory pain, DDD-024 for addiction, and DDD-016 for neuropsychiatric disorders, serving patients with unmet medical needs in neurology and addiction medicine.
Life Sciences & Healthcare
Semnur Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, non-opioid products for pain management.
Biotech
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
Similar biotechnology company
Centrexion Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel non-opioid therapeutics for the treatment of chronic pain and painful conditions.
Similar biotechnology company
Undaunted Bio, Inc. is an AI-driven drug repurposing company headquartered in Pittsburgh, United States, focused on treatments for neuropathic pain.
Similar biotechnology company
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Similar biotechnology company
Allay Therapeutics, Inc. is a biotechnology company headquartered in San Jose, United States, that focuses on developing advanced pain management products.
Similar biotechnology company
Amygdala Neurosciences Inc is an independent small biopharmaceutical company headquartered in San Francisco, California. Its mission is to invent and develop first-in-class therapeutics.
Similar biotechnology company
Vibrant Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, with operations in China. Founded in July 2019, the firm focuses on revolutionizing protein drug discovery and developing next-generation prodrugs with precise targeting.
Similar biotechnology company
Regenacy Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts. The company focuses on developing breakthrough treatments for diabetic neuropathies and other debilitating conditions.
Biotech
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Similar biotechnology company
Amplica Bio, Inc. is a biotechnology company that develops next-generation biologics and therapies aimed at targeting difficult diseases. The company engages in drug engineering to address challenging therapeutic targets.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Amalgent Therapeutics, LLC and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Amalgent Therapeutics, LLCand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →